The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin
Open accessAbstract
Vitiligo is an autoimmune disease of the skin causing disfiguring patchy depigmentation of the epidermis and, less commonly, hair. Therapeutic options for vitiligo are limited, reflecting in part limited knowledge of disease pathogenesis. Existing mouse models of vitiligo consist of hair depigmentation but lack prominent epidermal involvement, which is the hallmark of human disease. They are thus unable to provide a platform to fully investigate disease mechanisms and treatment. CD8+ T cells have been implicated in the pathogenesis of vitiligo and expression of interferon-gamma (IFN-γ) is increased in the lesional skin of patients, however it is currently unknown what role IFN-γ plays in disease. Here, we have developed an adoptive transfer mouse model of vitiligo using melanocyte-specific CD8+ T cells, which recapitulates the human condition by inducing epidermal depigmentation while sparing the hair. Like active lesions in human vitiligo, histology of depigmenting skin reveals a patchy mononuclear infiltrate and single-cell infiltration of the epidermis. Depigmentation is accompanied by accumulation of autoreactive CD8+ T cells in the skin, quantifiable loss of tyrosinase transcript, and local IFN-γ production. Neutralization of IFN-γ with antibody prevents CD8+ T cell accumulation and depigmentation, suggesting a therapeutic potential for this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C.-C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 760
Orchestrating the orchestrators: chemokines in control of T cell traffic
Bromley, S. K., Mempel, T. R., & Luster, A. D. (2008) · Nature Immunology · doi:10.1038/ni.f.213 · Cited by 593
Interstitial leukocyte migration and immune function
Friedl, P., & Weigelin, B. (2008) · Nature Immunology · doi:10.1038/ni.f.212 · Cited by 587
Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., Wietze van der Veen, J. P., Bos, J. D., Melief, C. J. M., Vyth-Dreese, F. A., & Luiten, R. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.32 · Cited by 543
Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.277 · Cited by 493
Andersen, M. H., Schrama, D., thor Straten, P., & Becker, J. C. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700001 · Cited by 484
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo
Ogg, G. S., Rod Dunbar, P., Romero, P., Chen, J.-L., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1203 · Cited by 460
Taïeb, A., & Picardo, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0804388 · Cited by 352
Zhang, S., Boisson‐Dupuis, S., Chapgier, A., Yang, K., Bustamante, J., Puel, A., Picard, C., Abel, L., Jouanguy, E., & Casanova, J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00698.x · Cited by 321
Cited by
Ezzedine, K., Eleftheriadou, V., Whitton, M., & van Geel, N. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60763-7 · Cited by 943
Bergqvist, C., & Ezzedine, K. (2020) · Dermatology · doi:10.1159/000506103 · Cited by 799
CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin
Cheuk, S., Schlums, H., Gallais Sérézal, I., Martini, E., Chiang, S. C., Marquardt, N., Gibbs, A., Detlofsson, E., Introini, A., Forkel, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.009 · Cited by 678
“, 2008), whereas vitiligo presents with persistent depigmentations attributed to local interferon-g (IFN-g) production and T cell-mediated killing of melanocytes (Harris et al., 2012; Rashighi et al., 2014; van den Boorn et al., 2009).”
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Self-citationJAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M.-W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007811 · Cited by 518
Self-citationNew discoveries in the pathogenesis and classification of vitiligo
Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G., & Harris, J. E. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.048 · Cited by 476
Self-citationPicardo, M., Dell'Anna, M. L., Ezzedine, K., Hamzavi, I., Harris, J. E., Parsad, D., & Taieb, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.11 · Cited by 326
Self-citationTwo Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
Rosmarin, D., Passeron, T., Pandya, A. G., Grimes, P., Harris, J. E., Desai, S. R., Lebwohl, M., Ruer-Mulard, M., Seneschal, J., Wolkerstorfer, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118828 · Cited by 316
Self-citationEmerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
Mechanisms of melanocyte death in vitiligo
Chen, J., Li, S., & Li, C. (2021) · Medicinal Research Reviews · doi:10.1002/med.21754 · Cited by 307
Anatomically distinct fibroblast subsets determine skin autoimmune patterns
Xu, Z., Chen, D., Hu, Y., Jiang, K., Huang, H., Du, Y., Wu, W., Wang, J., Sui, J., Wang, W., et al. (2022) · Nature · doi:10.1038/s41586-021-04221-8 · Cited by 305
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
Richmond, J. M., Strassner, J. P., Zapata, L., Garg, M., Riding, R. L., Refat, M. A., Fan, X., Azzolino, V., Tovar-Garza, A., Tsurushita, N., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7710 · Cited by 301
Self-citationVitiligo: A focus on pathogenesis and its therapeutic implications
Bergqvist, C., & Ezzedine, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15743 · Cited by 277
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
Boniface, K., Seneschal, J., Picardo, M., & Taïeb, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8622-7 · Cited by 272
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
Rosmarin, D., Pandya, A. G., Lebwohl, M., Grimes, P., Hamzavi, I., Gottlieb, A. B., Butler, K., Kuo, F., Sun, K., Ji, T., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30609-7 · Cited by 271
Self-citationJAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3
Boniface, K., Jacquemin, C., Darrigade, A.-S., Dessarthe, B., Martins, C., Boukhedouni, N., Vernisse, C., Grasseau, A., Thiolat, D., Rambert, J., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.08.038 · Cited by 263
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow, B. G., & King, B. A. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1520 · Cited by 259
T cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Qi, F., Liu, F., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790125 · Cited by 203
Resident Memory T Cells in Autoimmune Skin Diseases
Ryan, G. E., Harris, J. E., & Richmond, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652191 · Cited by 132
Self-citationFaraj, S., Kemp, E. H., & Gawkrodger, D. J. (2022) · Clinical and Experimental Immunology · doi:10.1093/cei/uxab002 · Cited by 94
Upadhya, S., Andrade, M. J., Shukla, V., Rao, R., & Satyamoorthy, K. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103841 · Cited by 27
Metadata
- Authors
- Harris, J. E., Harris, T. H., Weninger, W., John Wherry, E., Hunter, C. A., & Turka, L. A.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 132
- Issue
- 7
- Pages
- 1869-1876
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2097803930
- Cited by
- 389
- References
- 20
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.